Intravenous Iron Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Region and Competition, 2020-2030F

Description

The Global Intravenous Iron Drugs Market was valued at USD 2.46 Billion in 2024 and is projected to reach USD 3.39 Billion by 2030, registering a CAGR of 5.70%. Intravenous (IV) iron therapy has emerged as a critical alternative for patients who cannot tolerate or respond inadequately to oral iron supplements. This approach is gaining prominence in hospital settings, oncology departments, and dialysis centers where rapid iron restoration is essential.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 2.46 Billion
Market Size 2030	USD 3.39 Billion
CAGR 2025-2030	5.70%
Fastest Growing Segment	Iron Dextran
Largest Market	North America

The growing prevalence of anemia related to chronic conditions such as chronic kidney disease (CKD), inflammatory bowel disease (IBD), heart failure, and cancer is a major factor propelling demand. The introduction of safer, next-generation IV iron formulations has also improved clinical adoption by reducing adverse reactions and eliminating the need for test dosing. These advancements, combined with increasing awareness among healthcare professionals, are enhancing the appeal and accessibility of IV iron therapy in both developed and developing healthcare systems.

Key Market Drivers

Growth in Healthcare Industry

The rapid growth of the global healthcare sector continues to be a fundamental driver of the intravenous iron drugs market. With annual revenues exceeding USD 4 trillion, the healthcare industry includes key segments like pharmaceuticals, biotechnology, and diagnostics-each contributing significantly to the expansion of IV therapies.

Chronic diseases such as CKD, IBD, and cancer are increasingly diagnosed and treated as healthcare infrastructure improves globally. This has elevated the demand for iron supplementation, particularly in cases of iron-deficiency anemia that require immediate and effective intervention. By 2026, the number of hospitals worldwide is projected to reach 215,977, driven primarily by growth in regions like China, the Far East, and parts of Africa and the Middle East. With rising numbers of specialty clinics, diagnostic centers, and infusion-equipped facilities, the uptake of IV iron therapies is becoming more widespread, further fueling market momentum.

Key Market Challenges

High Cost of Treatment

A major hurdle facing the intravenous iron drugs market is the relatively high cost of treatment. Newer formulations such as ferric carboxymaltose and iron isomaltoside entail higher costs than conventional oral supplements. These expenses encompass drug prices, administration services, medical staff, and monitoring post-infusion, especially in hospital or clinic settings.

This cost factor poses a significant barrier in resource-limited countries where public health budgets are constrained. Even in advanced healthcare systems, variations in insurance coverage and high out-of-pocket costs can impede access to IV iron therapies. These economic barriers restrict wider adoption and make cost-containment strategies critical to expanding market reach.

Key Market Trends

Increasing Focus on Maternal and Pediatric Health

A notable trend influencing the intravenous iron drugs market is the growing emphasis on improving maternal and pediatric health outcomes. Iron-deficiency anemia remains prevalent among pregnant women and children, particularly in low- and middle-income countries. Sub-Saharan Africa alone accounts for roughly 70% of global maternal deaths, underlining the urgent need for effective interventions.

IV iron therapy is increasingly recognized as a preferred treatment for moderate to severe anemia during pregnancy, especially when oral supplements prove ineffective. Timely administration helps reduce the risk of complications such as low birth weight, preterm labor, and postpartum hemorrhage. This trend is supported by heightened awareness among healthcare professionals and the inclusion of IV iron in prenatal care protocols, signaling continued market growth in this segment.

Key Market Players

AMAG Pharmaceuticals, Inc.
Vifor Pharma Management Ltd.
Daiichi Sankyo Company, Limited
Rockwell Medical Inc.
Allergan PLC
Pfizer Inc.
Nippon Shinyaku Co.
Novartis International AG
Takeda Pharmaceutical Company Limited
Bausch Health Companies Inc.

Report Scope

In this report, the Global Intravenous Iron Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Intravenous Iron Drugs Market, By Product:

Iron Dextran
Ferric Gluconate
Iron Sucrose
Ferric Carboxymaltose
Iron Isomaltoside 1000
Ferumoxytol

Intravenous Iron Drugs Market, By Application:

Intestinal Malabsorption Syndromes
Inflammatory Diseases
Gastrectomy/Bariatric Surgery
Anemia
Osier-Weber-Rendu Disease
Angiodysplasia
Pregnancy
Others

Intravenous Iron Drugs Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Intravenous Iron Drugs Market.

Available Customizations

Global Intravenous Iron Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Intravenous Iron Drugs Market

5. Global Intravenous Iron Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product (Iron Dextran, Ferric Gluconate, Iron Sucrose, Ferric Carboxymaltos, Iron Isomaltoside 1000, Ferumoxytol)
- 5.2.2. By Application (Intestinal Malabsorption Syndromes, Inflammatory Diseases, Gastrectomy/Bariatric Surgery, Anemia, Osier-Weber-Rendu Disease, Angiodysplasia, Pregnancy, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America Intravenous Iron Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Application
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Intravenous Iron Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product
    - 6.3.1.2.2. By Application
- 6.3.2. Mexico Intravenous Iron Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product
    - 6.3.2.2.2. By Application
- 6.3.3. Canada Intravenous Iron Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.2. By Application

7. Europe Intravenous Iron Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Application
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Intravenous Iron Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product
    - 7.3.1.2.2. By Application
- 7.3.2. Germany Intravenous Iron Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product
    - 7.3.2.2.2. By Application
- 7.3.3. United Kingdom Intravenous Iron Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product
    - 7.3.3.2.2. By Application
- 7.3.4. Italy Intravenous Iron Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product
    - 7.3.4.2.2. By Application
- 7.3.5. Spain Intravenous Iron Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product
    - 7.3.5.2.2. By Application

8. Asia Pacific Intravenous Iron Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Application
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Intravenous Iron Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product
    - 8.3.1.2.2. By Application
- 8.3.2. India Intravenous Iron Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product
    - 8.3.2.2.2. By Application
- 8.3.3. South Korea Intravenous Iron Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product
    - 8.3.3.2.2. By Application
- 8.3.4. Japan Intravenous Iron Drugs Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product
    - 8.3.4.2.2. By Application
- 8.3.5. Australia Intravenous Iron Drugs Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product
    - 8.3.5.2.2. By Application

9. South America Intravenous Iron Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Application
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Intravenous Iron Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product
    - 9.3.1.2.2. By Application
- 9.3.2. Argentina Intravenous Iron Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product
    - 9.3.2.2.2. By Application
- 9.3.3. Colombia Intravenous Iron Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product
    - 9.3.3.2.2. By Application

10. Middle East and Africa Intravenous Iron Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Application
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Intravenous Iron Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product
    - 10.3.1.2.2. By Application
- 10.3.2. Saudi Arabia Intravenous Iron Drugs Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product
    - 10.3.2.2.2. By Application
- 10.3.3. UAE Intravenous Iron Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product
    - 10.3.3.2.2. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Intravenous Iron Drugs Market: SWOT Analysis

15. Porters Five Forces Analysis

15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products

16. Competitive Landscape

16.1. AMAG pharmaceuticals, Inc.
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (As Reported)
- 16.1.5. Recent Developments
- 16.1.6. Key Personnel Details
- 16.1.7. SWOT Analysis
16.2. Vifor Pharma Management Ltd.
16.3. Daiichi Sankyo Company, Limited
16.4. Rockwell Medical Inc.
16.5. Allergan PLC
16.6. Pfizer Inc.
16.7. Nippon Shinyaku Co.
16.8. Novartis International AG
16.9. Takeda Pharmaceutical Company Limited
16.10. Bausch Health Companies Inc.